Genesis Therapeutics
Vyom Thakkar has a diverse work experience in the technology and research fields. Vyom started their career as a Software Engineering Intern at Veeva Systems in 2019. Vyom then worked as an Undergraduate Student Instructor at UC Berkeley College of Engineering from 2019 to 2020. In 2019, Vyom also conducted research as an Honors Undergraduate Researcher at the UC Berkeley Molecular Cell Biomechanics Laboratory, where they analyzed data from molecular dynamics simulations and created a guide for future projects. Vyom further expanded their research experience at Stanford University School of Medicine, working as a Researcher from 2019 to 2021. In 2020, Vyom joined Forward as a Software Engineer, where they worked until 2022. Currently, they are employed as a Software Engineer at Genesis Therapeutics starting from 2023.
Vyom Thakkar began their education at Mira Loma High School from 2012 to 2016, where they completed their International Baccalaureate degree. Vyom then pursued further studies at UC Berkeley College of Engineering from 2016 to 2020, earning a Bachelor of Science (BS) degree with a focus on Bioengineering, Electrical Engineering, and Computer Science.
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.